Results 71 to 80 of about 42,587 (212)

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

Rare Tumors, 2016
The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective ...
Carolina Valeria Mahuad, Maria de los Ángeles Vicente Repáraz, Marta E. Zerga, María Florencia Aizpurúa, Claudia Casali, Gonzalo Garate   +5 more
doaj   +1 more source

Breast Implant-Associated Anaplastic Large Cell Lymphoma

Case Reports in Pathology, 2020
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare, non-Hodgkin lymphoma which arises within the capsules of breast implants. These particular tumours have expression of CD30 and are negative for Anaplastic Lymphoma Kinase (ALK)
P. L. Moori, F. Ibison, D. Jacob, J. Iddon   +3 more
doaj   +1 more source

Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]

, 2016
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core   +1 more source

Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

Cancer Science, EarlyView.
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Akito Hata, Akira Kisohara, Shoichi Kuyama, Masafumi Yamaguchi, Asako Miwa, Shunichiro Iwasawa, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors [PDF]

, 2016
Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors.
Anthony Tolcher, Erkut Bahceci, Geoffrey Yuen, Howard A. Ball, Jung Wook Park, Michael L. Maitland, Patricia LoRusso, Sai-Hong Ignatius Ou, Tianhong Li   +8 more
core   +3 more sources

Perioperative Nivolumab in Resectable Non‐Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T

Cancer Science, EarlyView.
ABSTRACT In the randomized phase III CheckMate 77T study, perioperative nivolumab showed statistically significant and clinically meaningful improvement in event‐free survival (EFS) vs. placebo in patients with resectable, non‐metastatic non‐small cell lung cancer (NSCLC).
Fumihiro Tanaka, Yasutaka Watanabe, Shunichi Sugawara, Jiro Okami, Satoshi Muto, Morihito Okada, Yoshitsugu Horio, Masahiro Tsuboi, Yuki Sato, Kazuya Takamochi, Hidehito Horinouchi, Yuichi Tambo, Masahiro Seike, Kyoichi Okishio, Cinthya Coronado Erdmann, Padma Sathyanarayana, Stephanie Meadows‐Shropshire, Hiroyuki Ito   +17 more
wiley   +1 more source

Systemic ALK-positive anaplastic large cell lymphoma involving implant site: a fortuitous association

Autopsy and Case Reports, 2021
Anaplastic lymphoma kinase (ALK) positive, anaplastic large cell lymphoma involving the non-mammary implant is an extremely rare presentation.
Mayur Parkhi, Charanpreet Singh, Rajender Kumar, Pankaj Malhotra, Amanjit Bal   +4 more
doaj  

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients [PDF]

, 2017
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were ...
Antolini, Laura, Bernard, Lea, Ceccon, Monica, Chiriano, Gianpaolo, Cohen, Amos M., Deeren, Dries, Farina, Francesca, Gambacorti Passerini, Carlo, Giudici, Giovanni, Grube, Matthias, Guerra, Luca, King, Michael H., Messa, Cristina, Mologni, Luca, Mussolin, Lara, Ordemann, Rainer, Piazza, Rocco, Redaelli, Sara, Sala, Elena, Stasia, Alessandra, Steurer, Michael   +20 more
core  

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma [PDF]

, 2013
Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established.
Peter Reimer, Shanta Chawla
core   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source